Celtaxsys celtaxsys.com


Public list: Pharma Startups (6570) Rare Diseases (230)

Celtaxsys is a clinical-stage pharmaceutical development company focused on advancing novel foundational therapies to treat inflammation in rare, orphan designated diseases. The company's flagship investigational medicine, oral once daily acebilustat, is aimed at preserving lung function in cystic fibrosis (CF) by specifically modulating key aspects of a dysregulated (i.e. over-activated) immune response.

Celtaxsys is a clinical-stage pharmaceutical development company focused on advancing novel foundational therapies to treat inflammation in rare, orphan designated diseases. The company's flagship investigational medicine, oral once daily acebilustat...Show all

Company (Alive / Active)

Phone: 470-206-0153

Fax: 404-920-0701

201 17th Street
Suite 530
Atlanta, 30363
Georgia, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Celtaxsys $52.7M Jan 4, 2018
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Celtaxsys Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 9 investors

Competitors

Company Status Description Investors

VLST Corporation

Seattle, Washington, United States
Assets PurchasedVLST (Viral Logic Systems Technology) has developed a streamlined and efficient platform that rapidly yields biological therapeutic compositions of matter with a far greater likelihood of success in clinical trials, particularly in autoimmune and inflammatory disorders. The VLST approach combines bioinformatics and proteomics to provide a rapid and rational approach to identifying new targets for the development of biologic therapies. Moreover, the process used to identify targets also provides ...Show allLogin to see details

Larimar Therapeutics

Bala Cynwyd, Pennsylvania, United States
IPO / Went publicLarimar Therapeutics (Nasdaq: LRMR) is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.Login to see details
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Inhibitors of leukotriene a4 hydrolase Dec 13, 2017 Dec 10, 2019 Patent
Inhibitors of leukotriene a4 hydrolase Sep 14, 2017 Sep 03, 2019 Patent
Monamine and monoamine derivatives as inhibitors of leukotriene a4 hydrolase Dec 11, 2017 Aug 20, 2019 Patent
Methods of inhibiting leukotriene a4 hydrolase Nov 02, 2017 Jul 16, 2019 Patent
Inhibitors of leukotriene a4 hydrolase Dec 11, 2017 Feb 12, 2019 Patent
See all 24 patents